Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Titel:
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Auteur:
Abou-Alfa, Ghassan K Macarulla, Teresa Javle, Milind M Kelley, Robin K Lubner, Sam J Adeva, Jorge Cleary, James M Catenacci, Daniel V Borad, Mitesh J Bridgewater, John Harris, William P Murphy, Adrian G Oh, Do-Youn Whisenant, Jonathan Lowery, Maeve A Goyal, Lipika Shroff, Rachna T El-Khoueiry, Anthony B Fan, Bin Wu, Bin Chamberlain, Christina X Jiang, Liewen Gliser, Camelia Pandya, Shuchi S Valle, Juan W Zhu, Andrew X